SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Korn Ferry entered into a definitive Sale and Purchase Agreement on June 27, 2026, to acquire all issued and outstanding shares of Auxey Holdco Limited (AMS) for approximately £850 million ($1.1 billion) in combined cash and stock consideration, creating a global leader in talent and organizational consulting with over 16,000 colleagues.
View raw filing on EDGAR →Verizon entered into a transaction agreement with BT Group plc to form a 50/50 joint venture (NewCo) by contributing its international wireline connectivity and managed network services business, along with a $625 million cash payment. This constitutes a material disposition and restructuring of a business segment that will result in estimated charges of $700–$800 million in Q2 2026, making it a significant M&A activity requiring disclosure under Item 1.01 or 2.01 principles, even though disclosed under Item 7.01.
View raw filing on EDGAR →The filing discloses delivery of Letters of Demand on June 18, 2026, stating that the Company's judicial management orders constitute Events of Default under three indentures governing approximately $1.5B+ in convertible notes (Variable-Rate, 9.00%, and Adjustable-Rate). The filing explicitly states that "due to the occurrence of these Events of Defaults, an automatic acceleration of the principal amount of, and all accrued and unpaid interest on, all 1st Lien Notes and 2nd Lien Notes has occurred," triggering immediate demands for full payment. This is a material covenant breach and acceleration event that directly threatens the Company's financial obligations and solvency, particularly given the Company is already under judicial management.
View raw filing on EDGAR →Larimar announced submission of the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp for Friedreich's ataxia, along with positive long-term open-label study data showing sustained skin frataxin (FXN) levels and directional clinical improvements. This is a material regulatory and clinical milestone for a clinical-stage biotech company, but does not fit neatly into the specific event categories (not an earnings release, M&A activity, impairment, or other defined types). The disclosure centers on a significant product development and regulatory advancement that would affect a reasonable investor's assessment of the company's progress toward commercialization.
View raw filing on EDGAR →Jonathan Collins was appointed as Senior Vice President, Finance and Chief Financial Officer of Genesco, effective August 3, 2026, following a comprehensive search process. Collins brings 30+ years of financial leadership experience, including prior roles at Walmart and America's Car-Mart. The appointment includes a base salary of $550,000, target incentive of $412,500, and long-term incentive target of $825,000.
View raw filing on EDGAR →The exhibit announces the appointment of Dr. Srishti Gupta as Chief Executive Officer and Board member of NovaBridge Biosciences, effective July 1, 2026. While the announcement also discloses that Xi-Yong (Sean) Fu is stepping down as CEO, the principal disclosed action is Gupta's appointment to the CEO role. The disclosure emphasizes her extensive leadership experience across biopharmaceuticals and global health, and the Board's confidence in her ability to advance the company's pipeline and create shareholder value—a material change in executive leadership at a clinical-stage biopharmaceutical company.
View raw filing on EDGAR →REGENXBIO announced receipt of a $100 million milestone payment from AbbVie triggered by dosing the first patient in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec. This is a material financial event—a substantial cash inflow tied to a contractual milestone under the September 2021 Collaboration and License Agreement. While the payment relates to clinical trial progress (operational), the primary disclosure centers on the financial obligation and cash receipt, making it a financial event rather than operational. It does not fit the specific categories of debt issuance, dividend distribution, or impairment, so financial_other is most appropriate.
View raw filing on EDGAR →Zymeworks entered into a definitive Agreement and Plan of Merger on June 28, 2026, to acquire Theravance Biopharma for $17.00 per share (approximately $929 million in total cash consideration), including contingent value rights tied to future product monetization. The transaction adds YUPELRI® and associated royalty streams to Zymeworks' portfolio.
View raw filing on EDGAR →CIM Real Estate Finance Trust (CMFT) completed a transformational acquisition of CIM Group, LLC's real assets management business and investment portfolio on June 24, 2026, resulting in a change of control where CIM Group, LLC received 67.5% voting and economic ownership of the combined entity. The company changed its legal name to CIM Group, Inc., ceased REIT status, and now operates as a diversified real assets manager with over $30 billion in assets under management.
View raw filing on EDGAR →David Thompson was appointed Chief Financial Officer, Principal Accounting Officer, and Treasurer of CIM Group, Inc. (formerly CMFT) effective June 24, 2026, replacing Nathan D. DeBacker. Thompson received an equity award of 30,433.658 RSUs under the 2024 Manager Plan.
View raw filing on EDGAR →This press release announces the integration of Saber Money into OwlPay Harbor, expanding OwlTing's cross-border payment infrastructure into India's US$860 billion export economy with direct rupee settlement and Eurozone/UK payment access. The disclosure describes a material operational and strategic milestone—opening a major new payment corridor and revenue opportunity—that aligns with management's stated 2026 objective of converting infrastructure into production client relationships and revenue. While not a discrete M&A transaction, the integration represents a significant expansion of the Company's addressable market and operational capabilities.
View raw filing on EDGAR →Strategy Inc announced a revised dividend policy for its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC) with a rate increase to 12.00% effective July 1, 2026, and declared conditional cash dividends for July 31 and August 15, 2026. The announcement also covers repurchase programs for preferred and common stock, a BTC monetization program, and a USD Reserve policy.
View raw filing on EDGAR →4D Molecular Therapeutics entered into a Loan and Security Agreement with Hercules Capital on June 24, 2026, establishing a new term loan facility of up to $200 million maturing June 1, 2031. The agreement includes specified interest rates, facility charges, covenants, and security interests.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of the 2026 Annual Meeting of Shareholders held on June 23, 2026. The filing presents detailed voting results for the election of eight directors and ratification of Weaver and Tidwell, L.L.P. as independent auditor, including vote counts (FOR, AGAINST, ABSTAIN, and broker non-votes) for each matter. Shareholder vote results are material to investors as they reflect governance outcomes and board composition.
View raw filing on EDGAR →Evommune announced that its Phase 2b clinical trial of EVO756 failed to meet its primary endpoint in chronic spontaneous urticaria, leading the company to cease development in this indication while continuing evaluation in atopic dermatitis and migraine. This material clinical development setback represents a significant strategic pivot affecting the company's pipeline and investor assessment of its progress.
View raw filing on EDGAR →JATT II Acquisition Corp entered into a definitive Business Combination Agreement with Talawar Tx Inc. on June 29, 2026, whereby Merger Sub will merge with and into JATT, with JATT surviving as a wholly-owned subsidiary of Talawar. The transaction involves $285 million in combined proceeds ($60 million from trust account plus $225 million PIPE financing) and is expected to close in H2 2026, with the combined entity listing on Nasdaq under ticker "TLWR."
View raw filing on EDGAR →This press release announces the completion of Optimi's third commercial psilocybin export shipment to Australia (1,000 capsules of 5mg psilocybin for treatment-resistant depression), marking ongoing commercial revenue generation from a regulated market. The disclosure emphasizes the company's commercial-stage operations, expanding reimbursement coverage from public and private insurers, and the absence of serious adverse events. While this is an operational milestone reflecting the company's ability to execute its business model in a regulated psychedelic medicine market, it does not fit the discrete event categories (M&A, earnings release, executive changes, debt issuance, etc.) and is best classified as an operational business development event.
View raw filing on EDGAR →The Company completed a forward sale offering of 14,000,000 shares of common stock on June 17, 2026, with an additional 2,100,000 shares issued via exercise of an underwriter option on June 26, 2026. This represents a dilutive equity issuance totaling 16.1 million shares at $23.12325 per share, generating substantial proceeds for the Operating Partnership. The forward sale structure with multiple underwriters and forward purchasers is characteristic of a large equity capital raise, which is material to existing shareholders.
View raw filing on EDGAR →Eric Hyllengren was appointed as Chief Financial Officer effective July 13, 2026, with responsibility for Principal Financial Officer and Principal Accounting Officer roles. The appointment includes compensatory arrangements consisting of a base salary of $490,000, a 40% target bonus, and an option grant of 1,650,000 shares.
View raw filing on EDGAR →Fortune Brands Innovations appointed Jesse G. Singh as Chief Executive Officer and Class I Board member effective June 29, 2026, following a comprehensive search process. David V. Barry was appointed Executive Vice President and Chief Operating Officer, transitioning from his interim CEO role. Singh's compensation package includes a base salary of $1,100,000, a bonus target of 150%, and a long-term incentive award of $6,700,000.
View raw filing on EDGAR →A. Jayson Adair was appointed as Chief Executive Officer effective July 31, 2026, succeeding Jeffrey Liaw. This represents a significant leadership change at the company.
View raw filing on EDGAR →The filing discloses the results of the 2026 annual meeting of stockholders held on June 26, 2026, which is the required Item 5.07 disclosure. Although the meeting failed to achieve quorum and was adjourned without conducting any business—including director elections and auditor ratification—this is still a shareholder vote result disclosure. The failure to achieve quorum and the resulting holdover director arrangement is material to investors as it affects board composition and governance continuity.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Virginia National Bankshares' 2026 Annual Meeting of Shareholders held on June 25, 2026, including voting outcomes for three proposals: (1) election of 11 directors, (2) advisory approval of executive compensation, and (3) ratification of the independent auditor Yount, Hyde & Barbour, P.C. The filing presents detailed vote tallies (votes for, against, withheld, and broker non-votes) for each director nominee and proposal, which is the standard format for shareholder vote results disclosures under Item 5.07.
View raw filing on EDGAR →The filing discloses a declared distribution of $0.1361 per common share by Fidelity Core Real Estate Fund, payable to shareholders of record on June 30, 2026, with payment on or about July 22, 2026. This is a routine but material dividend declaration for a real estate fund, which typically distributes income regularly to shareholders. The disclosure clearly falls under dividend_distribution.
View raw filing on EDGAR →The registrant conducted an unregistered private offering of 230,757.640 Class I common shares for approximately $4.7 million, relying on Section 4(a)(2) and Regulation D/S exemptions as part of a continuous offering.
View raw filing on EDGAR →The registrant declared a regular monthly distribution of $0.15 per share for Class I Shares, payable on or about July 9, 2026.
View raw filing on EDGAR →The Board of Directors has authorized a distribution to stockholders across multiple share classes (Class T, D, I, and X-1 common stock) with a record date of June 30, 2026 and payment date of approximately July 6, 2026. This is a routine but material dividend distribution to equity holders, disclosed under Item 8.01 (Other Events), with specific per-share amounts and distribution fees detailed for each class.
View raw filing on EDGAR →The filing discloses authorization by the board of directors of a distribution to stockholders of $0.1356 per share, payable on or about July 7, 2026, to shareholders of record as of June 30, 2026. This is a routine dividend distribution declaration by a real estate investment trust (REIT), which is material to investors as it affects shareholder returns and is a core component of REIT investor value propositions.
View raw filing on EDGAR →SPS issued $1.2 billion in aggregate principal amount of First Mortgage Bonds in two series (5.300% due 2036 and 5.875% due 2056) on June 29, 2026. This is a material creation of direct financial obligations governed by an indenture with a trustee, clearly constituting a debt issuance under Item 8.01 disclosure.
View raw filing on EDGAR →Zimmer Biomet entered into two new revolving credit facilities totaling $2.75 billion ($1.5 billion five-year and $1.25 billion 364-day) on June 26, 2026, and terminated two prior 2025 credit agreements. This refinancing materially affects the company's capital structure and liquidity position.
View raw filing on EDGAR →This press release announces a registered direct offering of 7,000,000 ADSs at $0.625 per share (gross proceeds ~$4.375 million) to a single institutional investor. The offering is registered under Form F-3 and represents a dilutive equity issuance. The company explicitly states it will use net proceeds for working capital and general corporate purposes, which is typical of capital-raising activity by smaller issuers. This is material to investors as it increases share count and dilutes existing shareholders.
View raw filing on EDGAR →The filing discloses the Board's unanimous election of Hilla Sferruzza as a director of Frontdoor, Inc., effective immediately, and her appointment to the Audit Committee. While the Item 5.02 section also describes her standard director compensation ($90,000 cash annually plus $180,000 in stock, plus $12,500 for Audit Committee service), the principal disclosed action is the appointment of a new director with significant finance and real estate expertise to the board and a key committee. This is a material governance event affecting board composition.
View raw filing on EDGAR →The 6-K discloses the closing of a warrant exercise window resulting in the issuance of 177,267 ordinary shares at an average price of approximately USD $121.57 per share, increasing share capital by nominal DKK 177,267. This represents a dilutive equity issuance triggered by warrant exercises, which is material to shareholders as it increases the share count and dilutes existing ownership. The disclosure of specific share count, pricing, and capital increase aligns with dilutive_issuance classification.
View raw filing on EDGAR →AGL Private Credit Income Fund closed a sale of 1,289,767.84 common shares for $30,000,000 on June 26, 2026, pursuant to subscription agreements with shareholders under Section 4(a)(2) and Regulation D. This unregistered equity offering materially increases the share count and dilutes existing shareholders.
View raw filing on EDGAR →The fund disclosed new investment commitments of approximately $102.5 million in debt instruments (Invited, Inc. and AWP Group Holdings, Inc.) made subsequent to March 31, 2026, along with portfolio characteristics as of June 23, 2026. This represents material capital deployment and portfolio composition changes for the investment fund.
View raw filing on EDGAR →The Board of Trustees declared a distribution of $0.60 per share payable to shareholders of record on June 23, 2026, with payment on July 30, 2026, and an option for reinvestment through the dividend reinvestment plan. This represents a material return of capital to shareholders.
View raw filing on EDGAR →FibroBiologics completed a private placement on June 25, 2026, raising approximately $3.0 million in gross proceeds through the issuance of 4,081,633 shares of common stock (or pre-funded warrants) and series A and B warrants exercisable for up to 8,163,266 additional shares, with potential for up to $6.0 million in additional proceeds. The securities were issued under Section 4(a)(2) and Regulation D exemptions and have not been registered under the Securities Act, creating significant dilution to existing shareholders.
View raw filing on EDGAR →Lincoln National Corporation completed a registered public offering of $500 million aggregate principal amount of 6.800% Fixed-to-Fixed Reset Rate Subordinated Notes due 2056 on June 29, 2026. The disclosure details the underwriting agreement, terms of the notes, interest rates, redemption provisions, and use of proceeds. This is a material creation of a direct financial obligation through debt issuance, distinct from a covenant breach or other debt-related event.
View raw filing on EDGAR →The Board of Directors has authorized a distribution to stockholders across five classes of common stock (Class A, D, I, P, and T) with a record date of June 30, 2026 and payment date of approximately July 17, 2026. The distributions range from $0.0947 to $0.1042 per share net of applicable servicing fees. This is a routine but material dividend distribution to equity holders, typical for a real estate income company (REIT structure implied by the multi-class distribution approach).
View raw filing on EDGAR →The Company announced a quarterly cash dividend of $0.10 per voting and non-voting common share, payable August 7, 2026 to shareholders of record on July 17, 2026. This is a routine but material dividend declaration that affects shareholder returns and is customarily disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →DBV Technologies disclosed a regulatory milestone update regarding its BLA (Biologics License Application) submission for VIASKIN® Peanut Patch in children aged 4-7 years. The company reported productive FDA engagement, confirmation that no additional data was requested, and a revised timeline for BLA submission to Q3 2026. This is a material operational/regulatory event affecting the company's product development trajectory and investor expectations, but does not fit the specific categories of earnings release, M&A activity, impairment, or other defined event types. The disclosure centers on a strategic regulatory milestone rather than a discrete operational restructuring or contract.
View raw filing on EDGAR →PennantPark Private Income Fund entered into an Amended and Restated Expense Limitation and Reimbursement Agreement with its Investment Adviser on June 29, 2026. This is a material definitive agreement (Item 1.01) that restructures the financial relationship between the Company and its adviser, establishing a framework for expense support payments and reimbursement obligations. While the agreement involves a material contract between related parties, it does not constitute M&A activity, debt issuance, or other specifically-named financial event types; it is a financial arrangement governing operating expenses and adviser compensation that would affect investor assessment of the Company's cost structure and cash flows.
View raw filing on EDGAR →Blackstone Infrastructure Strategies L.P. completed unregistered private placements of limited partnership units totaling approximately $365 million across multiple unit classes (Class I, S, D, and ACC Units) to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →Midera Food Processing entered into a $1.0 billion five-year credit agreement with Bank of America and other lenders on June 29, 2026, consisting of a $750 million U.S. dollar revolving facility and a $250 million multi-currency revolving facility. The company drew on these facilities and used cash on hand to make a $233 million distribution to Middleby Marshall Inc. in connection with its spin-off and transition to a stand-alone public company.
View raw filing on EDGAR →Blackstone Private Equity Strategies Fund L.P. and its feeder fund completed unregistered sales of limited partnership units totaling approximately $992.9 million in aggregate consideration on June 1, 2026, to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →Middleby announced the anticipated spin-off of Midera Food Processing as an independent publicly traded company, scheduled for July 6, 2026. This represents a material disposition and change of control of a significant business segment.
View raw filing on EDGAR →The Board approved amendments to employment agreements for three named executives (Christopher Giordano, Thomas Staab, and Stuart Rich) modifying their severance and change-in-control benefits, including base salary continuation, bonus payments, equity acceleration, and COBRA reimbursements. Concurrently, the Board adopted a Change in Control Plan and a Severance Plan establishing compensatory arrangements for eligible employees with similar benefits.
View raw filing on EDGAR →CSC issued $1,000,000,000 aggregate principal amount of 4.603% Fixed-to-Floating Rate Senior Notes due 2029, creating a new direct financial obligation. The disclosure includes the principal amount, interest rate, maturity date, net proceeds (~$995.5 million), underwriting agreement with Citigroup and Goldman Sachs, and the governing indenture documents. This is a material debt issuance under Item 2.03 (or disclosed under Item 8.01 as here), representing a significant capital-raising event for a major financial services company.
View raw filing on EDGAR →David J. Johnson, Jr. was elected as a director of Domtar Corporation by resolution of its sole shareholder on June 26, 2026. The disclosure centers on the appointment of a new director and provides his qualifications and background. While the filing also mentions a consulting agreement with Gemsbok Partners LLC, the principal disclosed action is the election of a director, making this an exec_appointment event. Director appointments are material to investors as they affect board composition and governance.
View raw filing on EDGAR →American Eagle Outfitters held its Annual Meeting of Stockholders on June 29, 2026, with stockholders voting on four proposals: election of Class I director Jay L. Schottenstein, ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2023 Stock Award and Incentive Plan. All four proposals passed with reported vote tallies.
View raw filing on EDGAR →